Trial Profile
Phase II Study of AB1010 in Patients With Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not Expressing FGFR3
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Masitinib (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors AB Science
- 19 Oct 2011 Status changed from active, no longer recruiting to completed.
- 17 Oct 2011 Results have been presented in an AB Science media release.
- 27 Mar 2009 New trial record